Study of Mesenchymal Autologous Stem Cells as Regenerative Treatment for Multiple Sclerosis
Status:
Recruiting
Trial end date:
2025-01-04
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to investigate neuroregenerative efficacy (proof of
concept) of intrathecal treatment with autologous MSCs as measured by neurophysiological
parameters in patients with progressive MS.
Secondary objectives are to assess neuroregenerative efficacy as measured by other
neurophysiological parameters as well as clinical, opthalmological and MRI modalities, and to
assess safety of the treatment procedure.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Haukeland University Hospital
Collaborators:
St. Olavs Hospital University Hospital of North Norway University Hospital Ulm University Hospital, Akershus University of Bergen